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Abstract
Background: Bromelain enhances anticancer impacts to chemotherapeutic agents. The ques-
tion as to whether bromelain does promote in-vitro cytotoxic and proapoptotic effects of cispla-
tin on human prostatic carcinoma PC3 cell line was investigated. Materials and Methods: PC3 
(human prostatic carcinoma) cells were treated either single or in combination with bromelain 
and/or cisplatin. MTT, clonogenic assay, flow cytometry and real-time quantitative polymerase 
chain reaction were used to investigate cell viability, colony formation, proapoptotic poten-
tial and p53 gene expression, respectively. Results: Cisplatin (IC10) combined with bromelain 
(IC40) significantly affected PC3 cell viability, inhibited colony formation, as well increased 
p53 proapoptotic gene expression compared to cisplatin single treatment. Nevertheless, brome-
lain-cisplatin chemoherbal combination did not display any additive proapoptotic effect com-
pared to single treatments. Conclusion: Bromelain-cisplatin chemoherbal combination demon-
strated synergistic in-vitro anticancer effect on human prostatic carcinoma cell line, PC3, that 
drastically reduced required cisplatin dose. [GMJ.2020;9:e1749] DOI:10.31661/gmj.v9i0.1749
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Introduction
Prostatic cancer is the second prevalent male malignancy. Sustained by prostatic 
anarchic epithelial cell proliferation, this type 
of cancer presents higher rates of cell prolif-
eration with the advanced age, and portends 
a high propensity to metastasize [1]. Surgery, 
electrochemotherapy, radiotherapy, inhib-
iting hormone therapy, and chemotherapy 
comprise the mainstay of multi-disciplinary 
anticancer therapeutics [2, 3]. Approaching 
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a 5-year survival lower than 50%, the fate 
of this cancer is clouded by resistance to 
chemotherapy. Cisplatin, a platinum-based 
chemical drug (cis-diamminedichloroplat-
inum or CDDP) is widely used in various 
anticancer chemotherapy protocols, such as 
in the case of ovarien, cervical and prostat-
ic cancer [4]. As a restrictive clinical issue, 
serious cisplatin side effects (nephrotoxicity, 
myelosuppression, ototoxicity, anaphylactic 
reactions, peripheral neuropathies, and hy-
pomagnesemia) can jeopardize the therapeu-
tic pursuit, inflicting substantial reduction in 
recommended therapeutic drug titrations [5]. 
In view of alleviating side effects, enhancing 
clinical tolerance, and boosting anticancer 
properties of chemotherapy, it was sought to 
take advantage from combination of natural 
herbal products to chemical drugs [6, 7]. Pre-
vious studies reporting on chemoherbal an-
ticancer combination indicated encouraging 
results. Extricated from pineapple (Ananas 
comosus), bromelain is a cysteine proteinase 
distinguished to display in-vitro anticancer 
properties such as inhibition effects on cell 
proliferation, as well apoptotic potential [8]. 
Bromelain as a mixture of proteases, has 
long been used in natural medicine across the 
globe. Anti-inflammatory, fibrinolitic, im-
munomodulatory and anticancer properties 
of bromelain were reported aside its classi-
cal beneficial effects on digestion, debriding 
burn scars and promoting action on wound 
healing process [9]. The bromelain antican-
cer properties were reported by a few clin-
ical evidences; yet, mainly investigated by 
in-vivo animal models as well in-vitro studies 
in a wide array of animal or human cancer 
cell lines [10]. Different mechanisms to bro-
melain anticancer potency were advanced. 
Pertaining to observed feature as to inhibit 
cell proliferation, undermine invasiveness, 
and promote apoptosis to neoplastic cells, 
a more complex and intricated anticancer 
mechanism of action involving multiple 
pathways was assigned to bromelain, which 
signalizations remain the focus of ongoing 
researches cells [11]. This study was de-
signed to investigate the in-vitro bromelain 
anticancer effects alone or in chemoherbal 
combination with cisplatin on human pros-
tatic carcinoma cell line, PC3.
Materials and Methods
Human Prostatic Carcinoma, PC3, Cell Cul-
ture
PC3 human prostatic carcinoma cell line was 
purchased from the Pasteur Institute (Tehran/ 
Iran). Cells were grown using Roswell Park 
memorial Institute (RPMI)-1640 (Life Tech-
nologies, California, USA) as the culture 
medium, supplemented with heat-inactivated 
10% FBS, 1% antibiotics (100 U/ml of peni-
cillin and streptomycin) (Life Technologies, 
California, USA) at 37°C, 98% humidity, 
under 5% CO2 partial pressure. Cells were 
trypsinized and passaged prior reaching cel-
lular confluence.
Bromelain and Cisplatin Stock Solution 
Preparation
Bromelain and cisplatin were sourced from 
Merck (Merck CO., Darmstadt, Germany). 
The stock solution to bromelain and cisplatin 
was prepared by dilution using sterile deion-
ized water. Stock concentrations for bro-
melain and cisplatin were 30µM and 250µM, 
respectively. The stock solutions were kept 
at 4°C and away from lightening. Subsequent 
required concentrations were obtained by di-
luting stock solution with RPMI.
Single Treatment 
Each well of 96-well plates was filled with 
5×103 cells per 200µL from PC3 cell culture 
medium. The well plate was incubated over-
night under standard protocol. Subsequently, 
cells were treated with different concentra-
tions of bromelain (0 to 30 µM) or cisplatin 
(0 to 100µM) [12]. Cells were incubated at 
three incubation times: 24, 48, and 72 hours. 
Each single treatment was repeated three 
times in three independent experiments.
Bromelain-Cisplatin Chemoherbal Combi-
national Treatment
Wells filled and incubated with PC3 cell line 
were treated by four distinct combinational 
concentrations of bromelain and cisplatin as 
follow: I) bromelain IC10 plus  cisplatin IC40, 
II) bromelain IC20 plus cisplatin IC30 , III) 
bromelain IC30 plus cisplatin IC20, IV) bro-
melain IC40 plus cisplatin IC10. The treated 
cell were kept incubated for 48 hours. The 
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chemoherbal combinational treatment was 
repeated three times in three independent ex-
periments.
MTT Assay to Appraisal Cell Proliferation 
Inhibitory Effect
Assessment of PC3 cell proliferation inhib-
itory effect to single or combinational treat-
ments relied on MTT assay [3-(4,5-dimeth-
ylthiazol-2-yr)-2,5-diphenyl tetrazolium 
bromide]. To the latter end, MTT solution 
(5mg/mL) was added to wells followed by 
a mandatory 4-hours incubation. Cells were 
dissolved in 200 µL of dimethyl sulfoxide 
(DMSO) (Merck) that was incubated for 20 
minutes. Optical density of each well was 
measured using a microplate reader (Stat 
Fax-2100, Awarness Technology Inc, Flori-
da, USA) on the light-range of 490-570 nm 
[13].
Clonogenic Cell Assay
PC3 cells were seeded in 6-well plates (100 
PC3 cells per well) and incubated overnight. 
Cells were treated by single bromelain/cis-
platin, or bromelain-cisplatin chemoherb-
al combination, and kept incubated for 48 
hours. To form cell colonies, previously 
treated PC3 cells were incubated for 14 days 
(37°C, 98% humidity, under 5% CO2 partial 
pressure) and the culture medium (RPMI) 
was renewed every 48 hours. Visible colo-
nies were fixed with 70% ethanol and stained 
with 0.5% crystal violet to measure plating 
efficiency (PE). Cell culture efficiency was 
measured by the formula [yield efficien-
cy=(number of colonies formed / number of 
cultured cells) × 100]. The survival ratio for 
treatment groups was calculated using the 
formula [survival ratio=(efficiency of cul-
tures with treatment / efficiency of cultures 
without treatment) × 100) [14].
Annexin V-PI Staining to PC3 Cell Apoptosis 
Assay
PC3 cells were seeded in 6-well plates 
(2×105 cells per well) and incubated for 24 
hours. Reaching 75% cell confluence incu-
bated PC3 cells were treated with bromelain, 
cisplatin, and bromelain-cisplatin chemo-
herbal combination for an incubated time of 
48 hours. Dead or viable cells were trypsi-
naized, washed with phosphate-buffered sa-
line (PBS), and stained with annexin (BD 
Bioscience California, USA) for 30 minutes 
at room temperature. Cell analysis was per-
formed using a flowcytometer (CYFLOW 
space, Patrick, Germany) according to the 
manufacture′s protocol [13].  
 
Real-Time Polymerase Chain Reaction 
(PCR)
PC3 were seeded at a density of 6×105 
cells/well for 24 hours, and exposed to 
bromelain-IC40, cisplatin-IC10, and bre-
omelain-IC40 plus cisplatin-IC10 combina-
tion. In accordance to manufacture′s instruc-
tions, PC3 cells were harvested and lyzed 
with RotiZOL. Determination of mRNA con-
certation to each single or combinational 
treatment was undertaken using Nanodrop 
spectrophotometer (Thermo, USA). Reverse 
transcriptase was used to synthetize cDNA 
from 1 µg of total mRNA pool which was 
carried out using Prime Script™ reagent Kit 
(Takara Bio Inc., Japan) for cDNA synthe-
sis [13]. Real-time quantitative polymer-
ase chain reaction (RT-qPCR) expanded 
cDNA using SYBR® Green PCR Master 
Mix (Takara Bio Inc., Japan) in the pres-
ence of specific primers for p53 (forward: 
5′-CCCATCCTCACCATCATCACAC-3′; 
reverse: 5′-GCACAAACACGCACCT-
CAAAG3′), and, the glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) (forward: 
5′ACACCCACTCCTCCACCCTTTG3′; 
reverse: 5′GTCCACCACCCTGTTGCTG-
TA-3′). The primers (Eurogentec Seraing, 
Belgium) were designed using Oligo 7.0 
software (Molecular Biology Insights, Cas-
cade, Co, USA) and confirmed by the blast 
(NCBI). Rotor-Gene 3000 (Corbett, Austral-
ia) was used to detect expression of p53 gene 
for each of the concentrations. The tempera-
ture profile for the reaction was an initial de-
naturation stage of 95°C at 10 min, and then a 
three-step program was developed for 40 cy-
cles including 95°C for 10 S, 62°C for 15 S, 
and 72°C for 20 S, respectively. GAPDH, a 
housekeeping gene, was amplified separately 
for normalizing the data.
Data Processing 
Data were obtained from 3 independent rep-
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etitions to each single or combinational treat-
ment, data analysis was undertaken using 
SPSS (version 20, Inc, Chicago, IL, USA) and 
GraphPad Prism 6 (GraphPad Software Inc., 
San. Diego, CA, USA). Data are expressed 
as means±standard error (SE). Cell viability 
percentages were plotted against different 
bromelain and cisplatin concentrations, and 
their respective IC10, IC20, IC30, IC40, IC50 
were calculated by regression prohibit. Com-
bination index values (CI) were estimated 
using CompuSyn software (Combo SynInc, 
City, State, USA). Synergistic, additive, and 
antagonist effects were respectively defined 
by CI<1, CI=1, and CI>1. Means compari-
son was preceded by Kruskal-Wallis test and 
Dunn’s. Statistical significance was defined 
as P<0.05.
Results 
Cell Proliferation Inhibitory Effect of Single 
Treatment
PC3 cells were treated as for different in-
cubation times of 24, 48, and 72 hours with 
bromelain or cisplatin as a single treatment. 
Concentration ranges to single treatment for 
bromelain and cisplatin were 0, 0.5, 1, 2, 3.5, 
7, 14 , and 28 µM and 0, 0.1, 1, 5, 10, 20, 40, 
50 , and 100 µM, respectively. 
Bromelain Single Treatment
At three different incubation times, bromelain 
displayed significant cell inhibitory effect on 
PC3 cell viability in a dose and time-depend-
ent manner (P<0.05) (Figure-1). Bromelain 
50% inhibitory concentration (IC50) was ob-
tained for each of the three different incuba-
tion times of 24, 48 , and 72 hours as 3.5 µM, 
4.4 µM, and 0.8 µM respectively. Cisplatin 
single treatment: At three different incuba-
tion times, cisplatin displayed significant cell 
inhibitory effect on PC3 in a dose and time 
dependent manner (P<0.05) (Figure-1). Cis-
platin 50% inhibitory concentration (IC50) 
was obtained for each of the three different 
incubation times of 24, 48, and 72 hours as 
55.02 µM, 3.09 µM, and 10.5 µM respective-
ly.
Cell Proliferation Inhibitory Effect of Chemo-
herbal Combinational Treatment
Considering the obtained respective values 
of IC50 to each of the bromelain or cisplatin 
single treatments, the incubation time of 48 
hours was chosen to conduct chemoherbal 
combinational treatment. The latter was un-
dertaken at 4 different combinational concen-
trations as to obtain an additive IC score of 
50 (Table-1). The combination IV displayed 
significant inhibitory effect in comparison to 
the control and single treatment either with 
bromelain or cisplatin (Figure-2).
Effect of Chemoherbal Combination Treat-
ment on PC3 Colony Formation
According to the results of combinational 
treatment on cell proliferation inhibitory, the 
combination IV was applied to clonogenic 
assay. The single treatments with bromelain 
IC40 and cisplatin IC10 were simultaneously 
investigated (Figure-3). The combination IV 
Figure 1. PC3 Cell viability after treatment with a various concentration of (A) bromelain and (B) cisplatin for 48 hours. Data are ex-
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was significantly effective on clonogenic in-
hibition when compared to untreated control 
PC3 cells (P<0.05) and single cisplatin treat-
ment (P<0.05). There was no additive effect 
of combination IV compared to single bro-
melain treatment. 
Effect of Combinational Chemoherbal Treat-
ment on PC3 Apoptosis Induction
Chemoherbal combination IV was applied to 
assess the chemoherbal effect on PC3 apop-
tosis induction compared to the control and 
single treatment with cisplatin or bromelain. 
Chemoherbal combination resulted in signif-
icant apoptosis enhancement compared to the 
control PC3 (P<0.05). Chemoherbal combi-
nation effect on PC3 apoptosis  induction did 
not reach significant difference compared to 
each of the single treatments (Figure-4).
Effects Combinational Chemoherbal Treat-
ment on PC3 Apoptosis-Related Gene Ex-
pression 
Chemoherbal combination IV was investi-
gated in parallel with control PC3 and single 
treatment with bromelain or cisplatin (Fig-
ure-5). Chemoherbal combination resulted in 
significant higher expression of proapoptotic 
Table 1. The Value of CI (Combination Index) of PC3 Cell Line Treated with Combination of Bromelain 











Figure 2. PC3 cell viability after treatment with IC10, IC20, IC30, IC40 of  bromelain and cisplatin as a single or combinational treatment for 
48 hours. Data are expressed as mean±SE from 3 independent repetitions. 
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p53 gene compared to the control (P<0.01), as 
well with cisplatin single treatment (P<0.05).
Discussion
Behind the lung cancer, the prostatic neo-
plasm represents the second prevalent human 
male malignancy. The therapeutic armantari-
um against human prostatic cancer encom-
passes chemotheraphy, radiotherapy, 
brachytherapy, electro-chemotherapy, target-
ed therapy and surgery [3, 15]. Despite con-
tinuous effort and achievements witnesed in 
the last 4 decades, the prostatic anticancer 
therapy is fraught with a failure rate reaching 
30 to 50%. As a pillar to prostatic anticancer 
therapy, chemotherapy aims to inhibit cancer 
cell proliferation, promoting apoptosis in-
duction and increase radiosensitivity of the 
neoplastic cells. Chemotherapeutic agents ef-
fect through various mechanisms of action as 
to reduce the tumor size and increase tumor 
vulnerability [16]. In practice, the effective 
conduct of chemotherapy can nevertheless be 
bared by developing resistance to the chemo-
therapeutic agents, as well their attendant 
side-effects jeopardizing their clinical toler-
ance [17]. Occurence chemotherapy related 
side-effects accounts for sustanial  morbidity 
and mortality [18]. Seeking to overcome 
chemotherapy limitations, chemoherbal 
combinational treatment (CHCT) emerged as 
a potential solution by taking in advantage 
the inate anticancer properties of natural 
herbal medicine to chemotherapeutic agents. 
Rutin, curcumin, thymoquinone, ZnO nano-
particles and bromelain recently proved their 
potency to enhance cytotoxicity of chemo-
therapeutic agents on various human cell 
lines [7, 10,13, 19-21]. Of recent, the syner-
gistic or permissive anticancer potency of 
natural herbal products, reported by in-vitro 
investigations or animal models on human 
neoplastic cell lines, do provide new insights 
as to consider means and ways to modulate 
chemotherapy condut. The latter aimed to en-
hance clinical tolerance by lessening the re-
quired therapeutic dose of chemotherapeutic 
agents (chemoprotective effect), while boost-
ing their anticancer potency by activating 
new complementary mechanisms or poten-
tialising chemotherapeutic impact in a mul-
ti-modal course of actions [8-11]. The bro-
melain anticancer action through its 
anti-inflammatory property was suggested 
first by preventing tumorogenesis sustained 
by the process of chronic inflammation, 
hence considered being of chemopreventive 
potential [22]. Bromelain chemopreventive 
effects on human skin and colon tumorogen-
esis was reported [23]. Downregulation of 
NF-κB, Cox-2, and PGE2 in parallel with up-
regulaion of INF ᵞ, THF-α, IL-1ß and IL-6 
were demonstrated as main bromelain an-
ti-inflammatory modulatory pathways. Bro-
melain attributed anti-inflammatory modula-
tion (NF-κB, Cox-2, and PGE2 
downregulation) is considered to hindern 
neo-anginogenesis required to tumor pro-
gression. Further, the proteolytic properties 
Figure 3. Colony formation (A) untreated, (B) treated with 2.5 
µM bromelain, (C) treated with 1.5 µM cisplatin, (D) treated with 
2.5 µM bromelain and 1.5 µM cisplatin and (E) relative plating 
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of bromelain was advocated as to be the lead-
ing mechanism of its anticancer action [8]. 
Accordingly, bromelain displayed blocking 
cell adhesion, inhibiting cell migration and 
invasiveness on glioblastoma  [8, 11, 24-27]. 
The bromelain inhibitory effects on neoplas-
tic cell proliferation (cytostatic or cytotoxic) 
were widely documented on various animal 
or human neoplasms such as leukemia, lym-
phoma, sarcoma, melanoma, lung carcinoma, 
gastric-intestinal carcinoma, gliolastoma, 
breast cancer, epidermoid carcinoma, mela-
noma and malignant mesothelioma [16, 28, 
29]. Chang et al. demonstrated that bromelain 
Figure 4. (A) Analyzing annexin V-FITC/PI by Flow Cytometry, (B) total apoptosis cells treated with bromelain (2.5 μM), cisplatin (1.5 μM) 
or combination of bromelain (2.5 μM) plus cisplatin (1.5 μM) for 48 hours. Data expression: mean±SE.
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increased oxidative stress and superoxide 
production by 6-fold in bromelain treated hu-
man colorectal cancer cells as part of its an-
ti-proliferative mechanisms [27]. The latter 
study also reported on in-vitro bromelain ef-
fect on activation of macrophagy pathway 
and lysosome formation through increasing 
levels of autophagy-related proteins 
(ATG5/12, beclin, p62, and LC3I/II) leading 
to programming cell death. The microenviro-
mental anti-inflammatory properties of bro-
melain by uncoating cancer cells (depolym-
erizing MUC-1,fibrin and albumin) is thought 
to enhance tumor exposure to the host de-
fense by increasing lymphocyte-to-tumor ad-
hesion [30]. Bromelain showed be capable of 
counteracting MUC-1 onco-glycoprotein 
overexpression that should impart enhanced 
proliferation and antiapoptotic feature to can-
cer cells along with conferring invasiveness 
and chemoresistance to various human tum-
ors. The aptitude of bromelain to engage 
in-vitro human leukemia cell differentiation 
was already mechanisms reported. Addition-
naly, bromelain proved to be of radiosensitiz-
ing feature in 4T1 mouse breast cancer cell 
line [14]. In the current study, single-agent 
bromelain or cisplatin treatment displayed a 
significant dose and time-dependent effect on 
inhibition of PC3 cell proliferation at three 
different incubation times of 24, 48 and 72 
hours (Figure-1). Unaminously, the previous 
reports pointed out the dose and time–de-
pendant feature of bromelain mode of action 
on various cancer cell lines. In our study, we 
showed bromelain induced the cell prolifera-
tion reduction, which is in agreement with 
those previous studies [29, 31]. Bro-
melain-cisplatin CHCT effects on PC3 cell 
proliferation was studied at four different 
combinations with an additive IC score of 
50% at 48 hours incubation time (Table-1). 
The CHCT combination-IV (bromelain IC40 
plus cisplatin IC10) was the only combina-
tional treatment displaying a significant addi-
tive effect on inhibition of PC3 cell prolifera-
Figure 5. Changes in p53 gene expression treated with bromelain (2.5 μM), cisplatin (1.5 μM) or combination of bromelain (2.5 μM) plus 
cisplatin (1.5 μM) for 48 hours. Data expression: mean±SE (* P<0.05, ** P<0.01). 
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tion in comparison to the single-agent 
treatment with bromelain or cisplatin (Fig-
ure-2). The latter resulted in a 38 time lesser 
cisplatin dose compared to cisplatin IC50 
alone as to inhibit PC3 cell proliferation. Pil-
lai et al. showed that bromelain-cisplatin 
CHTC increased a significant cytotoxic ef-
fect on malignant peritoneal mesothelioma 
(PET and YOU cells) compared to cisplatin 
single-agent [32]. Similary, Pauzi et al. 
demonstered in-vitro synergistic effect of 
bromelain-cisplatin CHCT on human breast 
MDA-MB-231 cancer cells. Using a combi-
national concentrain of bromelain 2 μM plus 
cisplatin 1.5 μM, the authors concluded a 16 
time reduction in cisplatin dose compared to 
its IC50 dose [12]. These results are in line 
with the findings of present study, however, 
indicating the PC3 cell proliferation may be 
more sensitive to bromelain-cisplatin CHTC 
compare to MDA-MB-231 cancer cells. 
When compared to the control and cisplatin 
single-agent treatment, the additive effect of 
combination-IV (bromelain IC40 plus cispla-
tin IC10) on PC3 cell inhibition to colony for-
mation was noticed (Figure-3). Colony for-
mation of PC3 cells was inhibited 
significantly with bromelain-cisplatin combi-
nation compared to the cisplatin single-agent 
treatment; nevertheless, without significant 
difference when compared to the bromelain 
single-agent treatment. Nasiri et al. demon-
strated the clonogenic inhibitory effect of 
bromelain as a single-agent or in combina-
tion with superparamagnetic iron oxide nan-
oparticles (SPIONs) on human cervical can-
cer cell (Hela), human breast cancer 
(MDA-MB-231), and murine breast cancer 
(4T1). Our finding is in agreement with this 
previous study [33]. In the current study, bro-
melain as a single-agent or combination with 
cisplatin decreased the percentage of plating 
efficiency of PC3 cells (Figure-3). We found 
the similar results as the previously reported 
studies showing reduction in plating efficien-
cy of treated human cancer cells with cispla-
tin as a single agent [34] or  bromelain as a 
single-agent or in combination with SPIONs 
[33]. In the current in-vitro study, although 
CHCT resulted in higher expression of proap-
optotic p53 gene (compared to control PC3 
cells, bromelain or cisplatin single-agent 
treatments), the latter did not result in any ad-
ditive synergistic effect on promoting cell 
apoptotic induction using flow cytometry 
(Figure-4). The latter converged to the find-
ings reported by Pauzi et al, investigating 
bromelain-cisplatin CHCT on human breast 
MDA-231MB cancer cells, whereby the au-
thors discribed synergistic effect on cancer 
cell apoptosis compared to single-agent treat-
ment [12]. Nevertheless, bromelain-cisplatin 
CHCT showed activating multiple apoptotic 
pathways (signalization cascade) compared 
to single-agent treatment. Reducing expres-
sion of antiapoptotic regulators such as cIAP 
1, Bcl-2, catalase,clusterin, HO-1, livin, 
XIAP, HSP27 and claspin was also demon-
strated in human breast cancer line [12]; the 
latter in support of mithochondrial apoptotic 
pathway using bromelain-based CHCT. In 
the current study, expression of p53 proapop-
totic protein based on the results of RT-PCR 
was significantly increased using CHCT 
(combination-IV; bromelain IC40 plus cispla-
tin IC10) compared to each of the single-agent 
treatments (Figure-5). Upregulation of p53 
was observed with the  chemoherbal combi-
nation-IV (bromelain IC40 plus cisplatin 
IC10). P53 upregulation lead to higher PC3 
cell death using the combination-IV. We 
found similar findings to those previously re-
ported studies, showing upregulation in p53 
of treated human cancer cells  with bromelain 
as a single-agent treatment [29, 35] or in 
combination with cisplatin [12], n-acetyl-
cysteine [36] or SPIONs [33]. Other studies 
demonstrated increased expression of proap-
optotic proteins such as HSP60 with bro-
melain-based CHCT. Overexpression of 
HSP70 known as a cytoprotective protein 
was also demonstrated as part of bro-
melain-based CHCT ability to induce auto-
phagy [37]. In addition bromelain-based 
CHCT demonstrated increasing intracellular 
concentration of chemotherapeutic agents 
such as 5-FU as part of its presumed permis-
sive effects on chemotherapy [32].
Conclusion
Anticancer chemoherbal combinational 
treatment drives promising insights based 
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tions. Anticancer action of bromelain in-
volves modulating different pathways that 
does depend on the cancer cell type and the 
experimental protocol. In the current study, 
bromelain as single-agent or in chemoherbal 
combinational treatment with cisplatin dis-
played anticancer properties on human pros-
tatic carcinoma PC3 cell line, permetting to 
drastically reduce the in-vitro cisplatin dose. 
Taking together the available data to the an-
ticancer features of bromelain and advocated 
multiple modulatory pathways, it is incentive 
to pursuit the research as to fully elucide the 
reproducibility of the reported results in-vit-
ro, as well extending in-vivo studies on each 
type of human cancer cell lines.
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